Workup and Management of Vaginal Bleeding in Pregnancy
Immediate Assessment and Safety Considerations
Perform transvaginal ultrasound and obtain quantitative beta-hCG immediately—these are the two essential diagnostic tests that guide all subsequent management decisions. 1
Critical Safety Rule for Physical Examination
- Never perform digital pelvic or bimanual examination until ultrasound has excluded placenta previa, low-lying placenta, and vasa previa, as examination before imaging can precipitate catastrophic hemorrhage. 1, 2
- Speculum examination to assess for cervical lesions, polyps, or inflammation is appropriate after ultrasound excludes placental abnormalities. 1
First Trimester Bleeding (< 13 weeks)
Primary Diagnostic Workup
- Transvaginal ultrasound is superior to transabdominal ultrasound for early pregnancy evaluation and should be the primary imaging modality. 1
- Obtain quantitative beta-hCG level regardless of ultrasound findings. 1
- Order coagulation panel including fibrinogen in trauma cases. 2
Interpretation Algorithm Based on Ultrasound Findings
If intrauterine pregnancy is confirmed:
- Ectopic pregnancy is essentially ruled out (except rare heterotopic pregnancy). 1
- If subchorionic hemorrhage is present with viable pregnancy, schedule follow-up ultrasound in 1-2 weeks. 1
- Continue routine prenatal care with reassurance that 50% of first trimester bleeding results in viable pregnancy. 3
If pregnancy of unknown location (no intrauterine or ectopic pregnancy visualized):
- 80-93% will resolve as early intrauterine pregnancies or failed intrauterine pregnancies. 1
- 7-20% will later be diagnosed as ectopic pregnancies. 1
- Obtain serial beta-hCG measurements 48 hours apart. 1
- Repeat ultrasound when beta-hCG reaches the discriminatory threshold of 1,500-2,000 mIU/mL, at which point a normal intrauterine pregnancy must show a gestational sac on transvaginal ultrasound. 1
- Continue serial beta-hCG measurements until diagnosis is established. 1
Critical Diagnostic Limitations
- Ultrasound may miss up to 50% of placental abruptions and 74% of ectopic pregnancies initially, which is why serial beta-hCG monitoring is critical when the initial ultrasound is non-diagnostic. 1
Second and Third Trimester Bleeding (≥ 13 weeks)
Immediate Management Priorities
- For viable pregnancies (≥ 23 weeks), perform electronic fetal monitoring for at least 4 hours. 2
- Obtain obstetrical ultrasound to evaluate placental location and exclude placenta previa before any vaginal examination. 4, 2
- Assess maternal hemodynamic status and fetal well-being simultaneously. 2
Admission Criteria for Extended Monitoring (24 hours)
Admit patients with any of the following adverse factors: 2
- Uterine tenderness
- Significant abdominal pain
- Vaginal bleeding
- Sustained contractions (> 1 per 10 minutes)
- Rupture of membranes
- Atypical or abnormal fetal heart rate pattern
- High-risk mechanism of injury
- Serum fibrinogen < 200 mg/dL
Key Differential Diagnoses
Placenta previa:
- Classically presents as painless bleeding. 5
- Diagnosed on ultrasound; if found before 20 weeks, nearly 90% resolve by third trimester. 4
- Persistent previa in third trimester mandates pelvic rest and hospitalization if significant bleeding occurs. 4
Placental abruption:
- Most common cause of serious vaginal bleeding, occurring in 1% of pregnancies. 4
- May present with abdominal pain and bleeding. 5
- Management should not be delayed pending ultrasound confirmation, as ultrasound is not sensitive for diagnosis. 2
- May require rapid operative delivery to prevent neonatal morbidity and mortality. 4
Vasa previa:
- Rare but can result in fetal exsanguination with rupture of membranes. 4
Rh Status Management
- Administer anti-D immunoglobulin to all Rh-negative pregnant trauma patients. 2
- Perform Kleihauer-Betke test or equivalent to quantify maternal-fetal hemorrhage and determine need for additional doses of anti-D immunoglobulin. 2
Imaging and Radiation Considerations
- Radiographic studies including abdominal CT indicated for maternal evaluation should not be deferred or delayed due to concerns regarding fetal radiation exposure. 2
- Gadolinium-based contrast agents can be considered when maternal benefit outweighs potential fetal risks. 2